WARSAW, Ind., Nov. 09, 2023 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. (“OrthoPediatrics”) (NASDAQ: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, announced that Dave Bailey, President & Chief Executive Officer, and Fred Hite, Chief Operating Officer and Chief Financial Officer, are scheduled to participate in fireside chats at two upcoming investor conferences.
| Event: | Stifel 2023 Healthcare Conference |
| Format: | Fireside Chat |
| Date: | Tuesday, November 14, 2023 |
| Time: | 1:15 pm ET |
| Event: | Piper Sandler 35th Annual Healthcare Conference |
| Format: | Fireside Chat |
| Date: | Tuesday, November 28, 2023 |
| Time: | 3:00 pm ET |
An audio webcast of the discussion will be available online at the OrthoPediatrics’ investor relations website, http://ir.orthopediatrics.com. Additionally, a replay will be available after the event.
About OrthoPediatrics Corp.
Founded in 2006, OrthoPediatrics is an orthopedic company focused exclusively on advancing the field of pediatric orthopedics. As such it has developed the most comprehensive product offering to the pediatric orthopedic market to improve the lives of children with orthopedic conditions. OrthoPediatrics currently markets 53 surgical systems that serve three of the largest categories within the pediatric orthopedic market. This product offering spans trauma and deformity, scoliosis, and sports medicine/other procedures. OrthoPediatrics’ global sales organization is focused exclusively on pediatric orthopedics and distributes its products in the United States and over 70 countries outside the United States. For more information, please visit www.orthopediatrics.com.
Investor Contact
Philip Trip Taylor
Gilmartin Group
This email address is being protected from spambots. You need JavaScript enabled to view it.
415-937-5406
| Last Trade: | US$22.33 |
| Daily Change: | -0.13 -0.58 |
| Daily Volume: | 256,348 |
| Market Cap: | US$540.830M |
November 26, 2024 November 06, 2024 August 05, 2024 August 05, 2024 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
